Program
izalontamab brengitecan
Also written as “BL-B01D1”, “Iza-bren” and “BMS-986507”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Small Cell Lung Carcinoma · Triple Negative Breast Neoplasms · Breast Neoplasms · Carcinoma, Transitional Cell, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sichuan Biokin Pharmaceutical | 5050 open or running | phase 3since Oct 25, 2023 | Jan 4, 2022 | Nov 2026phase 3 · NCT06118333 |
| Bristol-Myers Squibb | 55 open or running | phase 3since Apr 8, 2025 | Sep 26, 2024 | Mar 13, 2028phase 3 · NCT06926868 |
- Named in Bristol-Myers Squibb’s own pipeline as
iza-bren
, phase 3, as of Oct 29, 2026 (source).
Also a collaborator on its studies: Baili-Bio (Chengdu) Pharmaceutical.
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- LicenseBristol Myers Squibb licensed it from SystImmune (Biokin), for outside mainland China, developed and sold jointly in the US.Announced Dec 11, 2023 · Source: SystImmune and Bristol Myers Squibb (release), Dec 11, 2023
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. Dates ahead are the sponsors’ estimates.
Not listed one by one: 37 earlier studies, Jan 4, 2022 to May 11, 2025.
- Dec 11, 2023Bristol Myers Squibb licensed it from SystImmune (Biokin)LicenseOutside mainland China, developed and sold jointly in the US · announced · SystImmune and Bristol Myers Squibb (release)
- May 20, 2025Phase 3 study in Carcinoma, Ovarian EpithelialSichuan Biokin Pharmaceutical · NCT06994195 · 450 planned · China
- Jun 20, 2025Phase 2 study in Uterine Cervical NeoplasmsSichuan Biokin Pharmaceutical · NCT07054567 · 96 planned · China
- Jul 31, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungBristol-Myers Squibb · NCT07100080 · 661 planned · United States, Argentina, Belgium and more
- Aug 5, 2025Phase 3 study in Urinary Bladder NeoplasmsBristol-Myers Squibb · NCT07106762 · 470 planned · United States, Argentina, Australia and more
- Mar 25, 2026Phase 3 study in Small Cell Lung CarcinomaSichuan Biokin Pharmaceutical · NCT07502300 · 562 planned · China
- Apr 21, 2026Phase 3 study in Esophageal Squamous Cell CarcinomaSichuan Biokin Pharmaceutical · NCT07554456 · 90 planned · China
- May 6, 2026Phase 3 study in Biliary Tract NeoplasmsSichuan Biokin Pharmaceutical · NCT07582315 · 538 planned · China
- Jun 7, 20264 phase 3 studiesSichuan Biokin Pharmaceutical · NCT07640789, NCT07648914, NCT07642024 and 1 more
- Jun 26, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungBristol-Myers Squibb · NCT07680790 · 850 planned · United States, Argentina, Australia and more
- Jul 20, 20263 phase 3 studiesSichuan Biokin Pharmaceutical · NCT07729956, NCT07739199, NCT07739186
- Aug 20, 2026Phase 3 study in Nasopharyngeal CarcinomaSichuan Biokin Pharmaceutical · NCT07783321 · 404 planned · China
- Aug 27, 2026Phase 2 study in Nasopharyngeal CarcinomaSichuan Biokin Pharmaceutical · NCT07797881 · 60 planned · China
- Sep 14, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungSichuan Biokin Pharmaceutical · NCT07827261 · 36 planned · China
- Oct 9, 2026Primary completion moved from 2026-08 to 2027-06Date moved laterphase 2 · +10 months · NCT06498986
Ahead
- Nov 2026Primary completion: phase 3 study in Nasopharyngeal CarcinomaSichuan Biokin Pharmaceutical · NCT06118333
- Dec 2026Primary completion: phase 3 study in Small Cell Lung CarcinomaSichuan Biokin Pharmaceutical · NCT06500026
- Dec 2026Primary completion: phase 2 study in Triple Negative Breast NeoplasmsSichuan Biokin Pharmaceutical · NCT06471205
- Dec 2026Primary completion: phase 2 study in Small Cell Lung CarcinomaSichuan Biokin Pharmaceutical · NCT06437509
TargetBeta
“A dual-targeted antibody-drug conjugate (ADC) consisting of a bispecific antibody directed against both the epidermal growth factor receptor (EGFR; HER1; ErbB1) and the epidermal growth factor receptor 3 (HER3; ErbB3) conjugated, via a cathepsin-B cleavable linker, to the camptothecin derivative …”NCIt, read by Claude
“A dual-targeted antibody-drug conjugate (ADC) consisting of a bispecific antibody directed against both the epidermal growth factor receptor (EGFR; HER1; ErbB1) and the epidermal growth factor receptor 3 (HER3; ErbB3) ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-EGFR/Anti-HER3 Bispecific Antibody-drug Conjugate AVZO-1418rule | avenzo-therapeutics-inc | phase 2 | 1 |
| CS5007rule | CStone Pharmaceuticals | phase 1 | 1 |
Studies
All 55 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07827261Carcinoma, Non-Small-Cell Lung · China | 2 | Not yet recruiting | Sichuan Biokin Pharmaceutical | Dec 2028 | 36 |
| NCT07797881Nasopharyngeal Carcinoma · China | 2 | Not yet recruiting | Sichuan Biokin Pharmaceutical | Dec 2030 | 60 |
| NCT07783321Nasopharyngeal Carcinoma · China | 3 | Not yet recruiting | Sichuan Biokin Pharmaceutical | Dec 2033 | 404 |
| NCT07739199Squamous Non-small-cell Lung Cancer · China | 3 | Recruiting | Sichuan Biokin Pharmaceutical | Dec 2029 | 326 |
| NCT07739186Non-squamous Non-small Cell Lung Cancer · China | 3 | Recruiting | Sichuan Biokin Pharmaceutical | Dec 2029 | 166 |
| NCT07729956Triple Negative Breast Neoplasms · China | 3 | Recruiting | Sichuan Biokin Pharmaceutical | Dec 2029 | 436 |
| NCT07680790Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Recruiting | Bristol-Myers Squibb | Dec 30, 2031 | 850 |
| NCT07648914Breast Neoplasms · China | 3 | Recruiting | Sichuan Biokin Pharmaceutical | Dec 2028 | 446 |
| NCT07642024Carcinoma, Non-Small-Cell Lung · China | 3 | Recruiting | Sichuan Biokin Pharmaceutical | Dec 2032 | 90 |
| NCT07641855Castration-resistant Prostate Cancer · China | 3 | Not yet recruiting | Sichuan Biokin Pharmaceutical | Dec 2028 | 180 |
| NCT07640789Carcinoma, Non-Small-Cell Lung · China | 3 | Recruiting | Sichuan Biokin Pharmaceutical | Dec 2030 | 418 |
| NCT07582315Biliary Tract Neoplasms · China | 3 | Recruiting | Sichuan Biokin Pharmaceutical | Dec 2028 | 538 |
| NCT07554456Esophageal Squamous Cell Carcinoma · China | 3 | Recruiting | Sichuan Biokin Pharmaceutical | Dec 2028 | 90 |
| NCT07502300Small Cell Lung Carcinoma · China | 3 | Recruiting | Sichuan Biokin Pharmaceutical | Dec 2029 | 562 |
| NCT07106762Urinary Bladder Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Bristol-Myers Squibb | Jan 26, 2029 | 470 |
| NCT07100080Carcinoma, Non-Small-Cell Lung · United States, Argentina, Belgium and more | 3 | Recruiting | Bristol-Myers Squibb | Dec 15, 2028 | 661 |
| NCT07054567Uterine Cervical Neoplasms · China | 2 | Recruiting | Sichuan Biokin Pharmaceutical | May 2027 | 96 |
| NCT06994195Carcinoma, Ovarian Epithelial · China | 3 | Recruiting | Sichuan Biokin Pharmaceutical | Jun 2027 | 450 |
| NCT06986785Advanced Hepatocellular Carcinoma · China | 2 | Recruiting | Sichuan Biokin Pharmaceutical | May 2027 | 74 |
| NCT06978114Advanced Biliary Tract Cancer · China | 2 | Recruiting | Sichuan Biokin Pharmaceutical | May 2027 | 46 |
| NCT06962787Kidney Neoplasms · China | 2 | Recruiting | Sichuan Biokin Pharmaceutical | May 2027 | 260 |
| NCT06926868Breast Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Bristol-Myers Squibb | Mar 13, 2028 | 600 |
| NCT06857175Carcinoma, Transitional Cell · China | 3 | Active, not recruiting | Sichuan Biokin Pharmaceutical | Jun 2027 | 515 |
| NCT06838273Carcinoma, Non-Small-Cell Lung · China | 3 | Active, not recruiting | Sichuan Biokin Pharmaceutical | Dec 2028 | 724 |
| NCT06787664Chordoma · China | 2 | Active, not recruiting | Sichuan Biokin Pharmaceutical | Jun 2027 | 27 |
| NCT06618287Lung Neoplasms · United States, Australia, Canada and more | 2 | Recruiting | Bristol-Myers Squibb | Feb 26, 2031 | 416 |
| NCT06598787Glioblastoma · China | 2 | Recruiting | Sichuan Biokin Pharmaceutical | Oct 2026 | 20 |
| NCT06500026Small Cell Lung Carcinoma · China | 3 | Active, not recruiting | Sichuan Biokin Pharmaceutical | Dec 2026 | 722 |
| NCT06498986Carcinoma, Non-Small-Cell Lung · China | 2 | Active, not recruiting | Sichuan Biokin Pharmaceutical | Jun 2027 | 76 |
| NCT06475300Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Sichuan Biokin Pharmaceutical | Jun 2027 | 570 |
| NCT06471205Triple Negative Breast Neoplasms · China | 2 | Recruiting | Sichuan Biokin Pharmaceutical | Dec 2026 | 52 |
| NCT06437522Squamous Cell Carcinoma of Head and Neck · China | 2 | Recruiting | Sichuan Biokin Pharmaceutical | Jun 2027 | 46 |
| NCT06437509Small Cell Lung Carcinoma · China | 2 | Recruiting | Sichuan Biokin Pharmaceutical | Dec 2026 | 66 |
| NCT06405425Carcinoma, Transitional Cell · China | 2 | Recruiting | Sichuan Biokin Pharmaceutical | Dec 2026 | 52 |
| NCT06382142Triple Negative Breast Neoplasms · China | 3 | Active, not recruiting | Sichuan Biokin Pharmaceutical | Jan 13, 2026 | 418 |
| NCT06382129Carcinoma, Non-Small-Cell Lung · China | 3 | Active, not recruiting | Sichuan Biokin Pharmaceutical | Dec 2026 | 698 |
| NCT06382116Carcinoma, Non-Small-Cell Lung · China | 3 | Active, not recruiting | Sichuan Biokin Pharmaceutical | Aug 2026 | 432 |
| NCT06343948HR+HER2- Breast Cancer · China | 3 | Active, not recruiting | Sichuan Biokin Pharmaceutical | Aug 2026 | 383 |
| NCT06304974Esophageal Squamous Cell Carcinoma · China | 3 | Active, not recruiting | Sichuan Biokin Pharmaceutical | Oct 17, 2025 | 497 |
| NCT06118333Nasopharyngeal Carcinoma · China | 3 | Active, not recruiting | Sichuan Biokin Pharmaceutical | Nov 2026 | 386 |
| NCT06042894Breast Neoplasms · China | 2 | Recruiting | Sichuan Biokin Pharmaceutical | Dec 2026 | 58 |
| NCT06006169Squamous Cell Carcinoma of Head and Neck · China | 2 | Recruiting | Sichuan Biokin Pharmaceutical | Dec 2026 | 186 |
| NCT06008054Esophageal Neoplasms · China | 2 | Recruiting | Sichuan Biokin Pharmaceutical | Dec 2026 | 376 |
| NCT05990803Uterine Cervical Neoplasms · China | 2 | Recruiting | Sichuan Biokin Pharmaceutical | Dec 2026 | 130 |
| NCT05965856Carcinoma, Transitional Cell · China | 2 | Recruiting | Sichuan Biokin Pharmaceutical | Dec 2026 | 52 |
| NCT05956587Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Sichuan Biokin Pharmaceutical | Dec 2026 | 121 |
| NCT05983432Carcinoma, Non-Small-Cell Lung · United States, France, Italy and more | 1 | Recruiting | Sichuan Biokin Pharmaceutical | Apr 20, 2030 | 540 |
| NCT05924841Small Cell Lung Carcinoma · China | 2 | Recruiting | Sichuan Biokin Pharmaceutical | Dec 2026 | 100 |
| NCT05880706Carcinoma, Non-Small-Cell Lung · China | 2 | Active, not recruiting | Sichuan Biokin Pharmaceutical | Jul 2027 | 198 |
| NCT05803018Ovarian Neoplasms · China | 2 | Recruiting | Sichuan Biokin Pharmaceutical | Dec 2026 | 38 |
| NCT05785039Urologic Neoplasms · China | 2 | Recruiting | Sichuan Biokin Pharmaceutical | Dec 2026 | 76 |
| NCT05470348Breast Neoplasms · China | 1 | Recruiting | Sichuan Biokin Pharmaceutical | Dec 2026 | 36 |
| NCT05262491Digestive System Neoplasms · China | 1 | Recruiting | Sichuan Biokin Pharmaceutical | Dec 2026 | 96 |
| NCT05393427Carcinoma, Renal Cell · China | 1 | Active, not recruiting | Sichuan Biokin Pharmaceutical | Dec 2025 | 4 |
| NCT05194982Neoplasm Metastasis · China | 1 | Recruiting | Sichuan Biokin Pharmaceutical | Dec 2026 | 570 |
How it is read
Names in the registry
- “BL-B01D1”, 49 entries
- “Iza-bren”, 4 entries
- “BMS-986507”, 1 entry
- “BL-B01D1 for Injection”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 15 studies
- Small Cell Lung Carcinoma, 4 studies
- Triple Negative Breast Neoplasms, 4 studies
- Breast Neoplasms, 4 studies
- Carcinoma, Transitional Cell, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.